Mengistu Belete, Deribe Kebede, Kebede Fikreab, Martindale Sarah, Hassan Mohammed, Sime Heven, Mackenzie Charles, Mulugeta Abate, Tamiru Mossie, Sileshi Mesfin, Hailu Asrat, Gebre Teshome, Fentaye Amha, Kebede Biruck
Federal Ministry of Health, Addis Ababa, Ethiopia.
Wellcome Trust Brighton & Sussex Centre for Global Health Research, Brighton & Sussex Medical School, Falmer, Brighton, UK.
Ethiop Med J. 2017;55(Suppl 1):45-54.
Lymphatic filariasis (LF) is one of the most debilitating and disfiguring diseases common in Ethiopia and is caused by Wuchereria bancrofti. Mapping for LF has shown that 70 woredas (districts) are endemic and 5.9 million people are estimated to be at risk. The national government's LF elimination programme commenced in 2009 in 5 districts integrated with the onchocerciasis programme. The programme developed gradually and has shown significant progress over the past 6 years, reaching 100% geographical coverage for mass drug administration (MDA) by 2016. To comply with the global LF elimination goals an integrated morbidity management and disability prevention (MMDP) guideline and a burden assessment programme has also been developed; MMDP protocols and a hydrocoele surgical handbook produced for country-wide use. In Ethiopia, almost all LF endemic districts are co-endemic with malaria and vector control aspects of the activities are conducted in the context of malaria programme as the vectors for both diseases are mosquitoes. In order to monitor the elimination, 11 sentinel and spot-check sites have been established and baseline information has been collected. Although significant achievements have been achieved in the scale up of the LF elimination programme, there is still a need to strengthen operational research to generate programme-relevant evidence, to increase access to morbidity management services, and to improve monitoring and evaluation of the LF programme. However, the current status of implementation of the LF national programme indicates that Ethiopia is poised to achieve the 2020 goal of elimination of LF. Nevertheless, to achieve this goal, high and sustained treatment coverage and strong monitoring and evaluation of the programme are essential.
淋巴丝虫病(LF)是埃塞俄比亚常见的最使人衰弱和致残的疾病之一,由班氏吴策线虫引起。淋巴丝虫病的分布图显示,70个县(区)为流行区,估计有590万人面临感染风险。国家政府的淋巴丝虫病消除计划于2009年在与盘尾丝虫病计划整合的5个县启动。该计划逐步发展,在过去6年中取得了显著进展,到2016年实现了大规模药物治疗(MDA)100%的地理覆盖。为了符合全球淋巴丝虫病消除目标,还制定了综合发病管理和残疾预防(MMDP)指南以及负担评估计划;编写了MMDP协议和鞘膜积液外科手术手册供全国使用。在埃塞俄比亚,几乎所有淋巴丝虫病流行区都同时流行疟疾,由于这两种疾病的传播媒介都是蚊子,因此活动中的病媒控制工作是在疟疾计划的背景下开展的。为了监测消除情况,已设立了11个哨点和抽查点,并收集了基线信息。尽管在扩大淋巴丝虫病消除计划方面取得了重大成就,但仍需要加强行动研究以产生与计划相关的证据,增加获得发病管理服务的机会,并改善对淋巴丝虫病计划的监测和评估。然而,国家淋巴丝虫病计划的当前实施状况表明,埃塞俄比亚有望实现2020年消除淋巴丝虫病的目标。尽管如此,要实现这一目标,高覆盖率和持续的治疗以及对该计划的有力监测和评估至关重要。